Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Osteosarcoma study set to benefit dogs and children
“Comparative oncology - the study of cancer treatments in multiple species - has the potential to deliver tremendous medical advances" - Dr Timothy Fan.

Researchers to explore the combination of immunotherapy and radiation 

US researchers are conducting a study into whether a dog’s immune system could be stimulated to eliminate osteosarcoma.

The team at the University of Illinois College of Veterinary Medicine hope their findings could lead to advances in not only treating canine patients but children too.

Study co-investigator and veterinary oncologist Dr Timothy Fan said: “Because there are similarities between canine osteosarcoma and human paediatric osteosarcoma, finding better treatment options for this form of cancer is equally important.”

Osteosarcoma is a highly aggressive, malignant bone tumour that most often occurs in one of the limbs. The disease affects around 10,000 dogs each year in the US, most of which are large or giant breeds.

“The first sign owners typically notice in their pets is lameness,” says Dr Kim Selting who is also working on the study. “Animals may also have swelling in the area of the tumour. These areas can be warm and painful to the touch.”

Current treatment options for canine osteosarcoma are radiation, amputation, chemotherapy or a combination of these methods. The veterinary surgeon works with the owner to design a treatment plan, tailored to the individual, that focuses on quality of life.

In the study, the team will assess a treatment method that combines an immunostimulatory molecule called CPG ODN - a molecule that has already shown promise as a component of cancer vaccines - with high-precision radiation.

The study will take place in three parts, looking first at a cell model, then a mouse model to see how the CPG molecule works in real animals. The findings from these studies will then be used to develop treatments for a small pilot study involving dogs.

“Comparative oncology - the study of cancer treatments in multiple species - has the potential to deliver tremendous medical advances,” Dr Fan continues. “This field is exploding.

“The National Cancer Institute has designated Illinois and 21 other academic oncology programs as part of the Comparative Oncology Trials Consortium, which plays an important role in human cancer research.”

Become a member or log in to add this story to your CPD history

Big Butterfly Count returns

News Story 1
 The world's biggest survey of butterflies is back for 2020!

Butterfly Conservation's Big Butterfly Count launches on Friday, 17 July and will run until Sunday 9 August. Members of the public can get involved by downloading the Big Butterfly Count App or recording results on a downloadable sheet available from bigbutterflycount.org/.

'It's a fantastic activity for people from three to 103 years and we'd encourage everyone to take 15 minutes in an appropriate outdoor space during sunny conditions to simply appreciate the nature around them and do their bit to help us understand butterfly populations,' said a Butterfly Conservation spokesperson. 

Click here for more...
News Shorts
New appointment at Dechra

Dechra Veterinary Products Ltd (Dechra) has announced a key appointment to support veterinary professionals across Northern Ireland and the Republic of Ireland.

Karen Hockley has been appointed as a telesales account manager and will provide the latest products, news and developments from Dechra. She joins the company from a large mixed practice in Northern Ireland where she was the branch manager.

Before that, Karen had worked for a multinational veterinary pharmaceutical company as a key account manager for Northern Ireland. She can be contacted at karen.hockley@dechra.com or 087 219 54 30.